Follow the Camurus AB share price and the full directors' dealings record of the company, a listed issuer based in Finland. Shares are listed on the FI market, under the supervision of FIN-FSA. Operating in the Health Care sector, Camurus AB has published 13 public disclosures. Market capitalisation: €37.6bn. The latest transaction was filed on 19 February 2026 (Purchase). Among the most active insiders: Fredrik Tiberg. Every trade is free.
13
Insider Decl.
n/a
Thresholds
€63,042
2 ops.
Buy Volume
€2m
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Camurus AB Strong Buy (bullish), based on 8 analysts. Average price target: SEK 776.75.
37Σ signal
Buys €63,042€2m Sells
Fundamental score
Ranked 8,402 of 28,752 companies
61.9
score / 100
Value
34
Quality
90
FCF yld2.0%
Earn yld2.0%
EV/EBITDA38.2x
ROE16%
Gross mgn93%
Net mgn32%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Camurus AB is a Swedish biopharmaceutical company focused on developing innovative treatments for chronic diseases. It is listed on the Stockholm Stock Exchange (XSTO).